Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

195.72 +1.53 (+0.79%)
Streaming Delayed Price Updated: 2:39 PM EDT, Oct 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,604,025
Open 194.24
Bid (Size) 195.71 (2)
Ask (Size) 195.74 (1)
Prev. Close 194.19
Today's Range 193.66 - 195.91
52wk Range 135.85 - 199.95
Shares Outstanding N/A
Dividend Yield 3.02%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Looking Into AbbVie's Recent Short Interest
Via Benzinga
Bausch + Lomb Sale Process Gains Momentum As TPG And Blackstone Join Forces
Private equity giants TPG and Blackstone are pursuing a potential $14 billion buyout of Bausch + Lomb. 
Via Benzinga

Performance

YTD
+22.47%
+22.47%
1 Month
+0.78%
+0.78%
3 Month
+16.48%
+16.48%
6 Month
+21.06%
+21.06%
1 Year
+32.94%
+32.94%

More News

Read More
2 Magnificent Dividend Stocks to Buy and Hold Forever
Via The Motley Fool
Prediction: These 2 High-Yield Dividend Stocks Will Outperform the S&P 500 Index in the Coming Decade
Via The Motley Fool
Topics Stocks
Exposures US Equities
Johnson & Johnson Dividend Stock Analysis - Saturday, Oct. 12
Via Talk Markets
There Are Only 28 S&P 500 Companies Warren Buffett Can't Buy Outright. Here's the Best of the Bunch for Income Investors.
Via The Motley Fool
Topics Stocks
Exposures US Equities
If You Invested $100 In This Stock 10 Years Ago, You Would Have $400 Today
Via Benzinga
AbbVie's Options: A Look at What the Big Money is Thinking
Via Benzinga
In-Depth Examination Of 11 Analyst Recommendations For AbbVie
Via Benzinga
AbbVie Stock Eyes New Highs: Analysts See Strong Growth Potential
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer
Via Benzinga
Biotech Stocks Poised For Another Big Move In Q4
Via Talk Markets
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Comparing AbbVie With Industry Competitors In Biotechnology Industry
Via Benzinga
Behind the Scenes of AbbVie's Latest Options Trends
Via Benzinga
3 Magnificent Dividend Stocks to Buy in October
Via The Motley Fool
Billionaires Are Loading Up on This High-Yield Dividend Stock. Should You?
Via The Motley Fool
2 Top Dividend Stocks Yielding 3% or More to Buy Without Hesitation Right Now
Via The Motley Fool
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
3 Industries Set To Explode When Interest Rates Drop
Via Talk Markets
Blue Shield of California Slashes Humira Biosimilar Prices in Landmark Deal
Via Benzinga
Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected
Via Benzinga
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
5 Best Dividend Growth Stocks to Buy in October
Via The Motley Fool
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
Via Investor Brand Network
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.